


YOU ARE INVITED TO JOIN US



# ESSENTIALS IN HEART FAILURE

## Primary Care Nurse | Virtual Meeting Series

Using a Hub & Spoke Model

**Presented by Jane Calligeros**

A series of 3 interactive educational meetings designed specifically to educate primary care nurses working in primary care clinics about Heart Failure (HF) as it relates to their day to day management of patients: disease awareness; recognition of signs and symptoms; identification and assessment of patients and treatment options. It is encouraged that you attend all meetings to obtain maximum benefit from this program.

MEETING	PRESENTATION	DATE   TIME
1	<b>Identification and Management of HF</b> Overview of HF, HF in general practice, How HF is diagnosed and treated. Role of nurses in reducing HF risk.	<b>Tuesday 6 October 2020</b> <b>12:00pm – 2:00pm</b>
2	<b>What does the patient conversation look like?</b>	<b>Tuesday 20 October 2020</b> <b>12:30pm – 1:30pm</b>
3	<b>Best Practice learning</b> Peer to Peer review of best practice sharing. How to enhance systems of care within your clinic.	<b>Tuesday 3 November 2020</b> <b>12:30pm – 1:30pm</b>

To register your attendance, please email your details including your Name, Practice, Role, Email address and Contact phone number to:

[jane.mcateer@novartis.com](mailto:jane.mcateer@novartis.com)

 **NOVARTIS**

## Meet the Speaker



### Jane Calligeros

Jane has 20 years of Nursing experience; the last ten years working in General Practice. She began her nursing career in 2000 after completing her Bachelor of Nursing in Newcastle. Jane followed her passion to Primary Healthcare in 2006 including Post Graduate qualifications in Chronic Disease Management in 2015.

Jane founded CDM Plus in 2015 with the purpose of helping practices better manage patients with chronic disease and promote activities that can help prevent and detect chronic disease. CDM Plus provides training and resources for General Practices and Aboriginal Medical Services throughout Australia.

Jane has a unique nursing background working in Emergency, Community, Occupational and Corporate Health before moving to Primary Healthcare. Her knowledge of funding mechanisms, Medicare Item Number requirements and development of system based processes to improve Chronic Disease Management makes her a valuable resource for Primary Care and continues to make CDM Plus leaders in their field.

For further information about this event, email: [jane.mcateer@novartis.com](mailto:jane.mcateer@novartis.com)

**To register your attendance, please email your details including your Name, Practice, Role, Email address and Contact phone number to:**

**[jane.mcateer@novartis.com](mailto:jane.mcateer@novartis.com)**

Your personal information will be processed in accordance with the Novartis Privacy Policy at <https://www.novartis.com.au/privacy-policy>. Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.

Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.

Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. August 2020. AU-13385. CRD3140.